---
document_datetime: 2023-09-21 18:29:50
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/procomvax-epar-procedural-steps-taken-authorisation_en.pdf
document_name: procomvax-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5261039
conversion_datetime: 2025-12-27 16:24:58.264182
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  company  Pasteur  Mérieux  MSD,  France,  submitted  on  10  February  1998  an  application  for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for  COMVAX  (later  changed  to  PROCOMVAX),  in  accordance  with  the  Centralised  Procedure falling within the scope of Part A of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993.

•

•

- On  17  November  1998,  the  Dutch  Health  Care  Inspectorate  issued  a  favourable  inspection report  in  which  it  was  concluded  that  the  manufacturer  of  the  active  substances  and  finished product of the combined vaccine, Merck &amp; Co. Inc. West Point, USA, complied with the EU GMP rules.

Medicinal product no longer authorised The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Dr. M. Haase Co-Rapporteur: Dr. E. Abadie Licensing status PROCOMVAX was given a Marketing Authorisation in United States of America on 2 October 1996. 2. Steps taken for the assessment of the product · The procedure started on 25 February 1998. · The Rapporteur's initial assessment report was circulated to all CPMP Members on 8 May 1998. · The Co-Rapporteur's initial assessment report was circulated to all CPMP Members on 12 May 1998. · The BWP during its meeting of 16-17 June 1998, discussed the major pharmaceutical objections and adopted a BWP Report to be transmitted to the CPMP. · The  CPMP,  during  its  meeting  of  23-24  June  1998,  adopted  the  CPMP  consolidated  list  of questions to be sent to the company. Also in this meeting, objections were raised with respect to the acceptability of the proposed tradename COMVAX. · The CPMP consolidated List of Questions was sent to the company on 25 June 1998. · Merck  &amp;  Co.  Inc.  facilities  in  West  Point,  Pennsylvania,  USA  (manufacturer  of  the  active substances and finished product), were inspected by the Dutch Health Care Inspectorate and the German  pharmaceutical  expert  on  31  August  to  3  September  1998.  Major  deficiencies  were identified for which an acceptable action plan to correct the deficiencies was requested. · The  company  submitted  the  responses  to  the  consolidated  list  of  questions  on  9  September 1998. · The Rapporteur's and Co-Rapporteur's joint assessment report on the company's responses to the list of questions was circulated to all CPMP Members on 19 October 1998. The objection to the tradename was addressed by the company in their letter of 16 October 1998 which was considered by the CPMP in its meeting of 20-22 October 1998. On 19 October 1998, the company submitted a proposal for a new name - PROCOMVAX. The new name was forwarded to the national contact points to be checked.

<div style=\"page-break-after: always\"></div>

- The CPMP in its meeting of 17-19 November 1998 discussed the outstanding clinical issues and agreed that an oral explanation would be necessary to address them.
- On 20 November 1998, the company requested a 'stop-of the-clock' in order to prepare for the oral explanation. The list of outstanding questions to be addressed at the oral explanation was sent to the company on 20 November 1998.

<!-- image -->

Medicinal product no longer authorised · The company provided supplementary written information addressing the outstanding questions to all the CPMP members on 27 November 1998. · On 15 December 1998, the company addressed the outstanding questions at an oral explanation. · The CPMP during its meeting of 15-17 December 1998, discussed the outstanding questions addressed during the oral explanation by the company. It was the view of the CPMP that the major safety issue had not been satisfactorily  resolved  and  that  further  explanation  regarding this issue was required. · On 16 December 1998, the company requested a 'stop-of the-clock' in order to provide further information  by  written  explanation.  The  list  of  outstanding  issue  to  be  addressed  by  written explanation was sent to the company on 18 December 1998. · On  4  January  1999,  the  company  submitted  further  written  explanation  in  response  to  the outstanding safety issue, to all CPMP members. · The Co-Rapporteur's assessment of the written explanation in response to the outstanding safety issue was circulated to all CPMP members on 18 January 1999. · The Rapporteur's assessment of the written explanation in response to the outstanding safety issue was circulated to all CPMP members on 19 January 1999. · The CPMP during its meeting on 26-27 January 1999, discussed the written explanations on the outstanding questions from the company. Amendments to the Summary of Product Characteristics,  and  the  follow-up  measures  to  be  undertaken  by  the  company  were  also discussed. · The company, Pasteur Mérieux MSD, provided on 26 January 1999, a letter of undertaking on the follow-up measures (pharmaceutical and clinical issues), to be fulfilled as requested by the CPMP. · During the CPMP meeting of 26-27 January 1999, the CPMP, in the light of the overall data submitted,  the  follow-up  measures  undertaken  by  the  company  and  the  scientific  discussion within the Committee, issued a positive opinion for the granting of a Marketing Authorisation for PROCOMVAX on 27 January 1999.